Announced details
Already implemented at multiple major pharmaceutical companies (the number of adopting companies is Not disclosed)
The AI Drug Discovery & Development Summit 2026 was attended by major pharmaceutical companies, biotechnology companies, academic institutions, and AI and GPU cloud companies from around the world. The event was organized by Kisaco Research.
A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed)
Boston, Massachusetts, United States (conference venue: Boston Marriott Copley Place)
The event demonstrated the potential for DDAIF's business expansion, and the company stated that it would further accelerate its global business development. The specific impact on sales and profit is Not disclosed
The company does not address Contract Value / Offering price.
AI Drug Discovery & Development Summit 2026、Kisaco Research
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT (Kibit) |
| Counterparty overview | The AI Drug Discovery & Development Summit 2026 was attended by major pharmaceutical companies, biotechnology companies, academic institutions, and AI and GPU cloud companies from around the world. The event was organized by Kisaco Research. |
| Applicable area | Drug discovery biology, Drug discovery chemistry, Clinical Trials, Discovery of novel target molecules, Indication discovery, Drug repositioning, Biomarker discovery |
| Registration number and expiry date | A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed) |
| Location | Boston, Massachusetts, United States (conference venue: Boston Marriott Copley Place) |
| Usage history | Already implemented at multiple major pharmaceutical companies (the number of adopting companies is Not disclosed) |
| Impact on Business Performance | The event demonstrated the potential for DDAIF's business expansion, and the company stated that it would further accelerate its global business development. The specific impact on sales and profit is Not disclosed |
| Source | AI Drug Discovery & Development Summit 2026、Kisaco Research |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company confirmed strong demand from pharmaceutical companies and research institutions worldwide for the discovery of novel drug target molecules, as well as strong demand for FRONTEO's AI technology. Recognition of its proprietary technology and research track record demonstrated DDAIF's competitiveness and potential for business expansion.